Nabriva Therapeutics plc
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nabriva Therapeutics plc (NASDAQ: NBRV) is an Ireland-based biopharmaceutical company focused on the development and commercialization of novel anti-infective agents to treat serious bacterial infections; its core products include XENLETA (lefamulin injection and tablets), the first systemic pleuromutilin antibiotic approved by the FDA for community-acquired bacterial pneumonia (CABP) in adults; and CONTEPO (fosfomycin for injection), a broad-spectrum epoxide antibiotic targeting complicated urinary tract infections (cUTIs) including acute pyelonephritis, with a New Drug Application pending before the FDA. Founded in 2006 as a spin-off from Sandoz GmbH's Antibiotics Research Institute in Vienna, the company maintains corporate headquarters at 25-28 North Wall Quay in Dublin, Ireland, with additional offices and laboratories in Vienna, Austria; King of Prussia, Pennsylvania; and other U.S. locations. Nabriva engages in global operations across North America, Europe, and select international markets, serving clinicians and patients with multi-drug resistant infections through innovative pleuromutilin and epoxide antibiotic classes; it also promotes and distributes partnered products such as SIVEXTRO (tedizolid phosphate) under an exclusive U.S. agreement with Merck. Recent strategic developments include the July 2024 sale of North American rights to CONTEPO to Meitheal Pharmaceuticals, encompassing all related intellectual property, regulatory data, and technology in exchange for upfront payment and U.S. net sales royalties; the divestiture of global XENLETA rights (excluding Greater China) to HKF, transferring substantially all associated assets; an exclusive distribution agreement for XENLETA with ER-Kim Pharmaceuticals in international markets; and Nasdaq delisting proceedings alongside a Form 15 filing in late 2024, reflecting a pivot to asset monetization and partnership-focused operations.
Aadi Bioscience (NASDAQ:AADI) versus Nabriva Therapeutics (NASDAQ:NBRV) Head-To-Head Analysis
Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast
7 Stocks to Sell as Banks Melt Down
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva's stock is up after sharing antibiotic news
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
Buying Penny Stocks Today? What You Need to Know
Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q4 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022